Back to top
more

Dynavax Technologies (DVAX)

(Real Time Quote from BATS)

$10.86 USD

10.86
388,835

+0.30 (2.84%)

Updated Jul 16, 2024 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for DVAX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Dynavax Technologies Corporation [DVAX]

Reports for Purchase

Showing records 41 - 60 ( 123 total )

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 41

04/22/2021

Company Report

Pages: 6

Pivotal Phase 3 Trial of Valneva''s COVID-19 Vaccine Candidate Adjuvanted With Dynavax''s CpG 1018 Initiated

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 42

04/06/2021

Daily Note

Pages: 3

Solid Phase 1/2 Initial Results Reported for VLA2001 Vaccine Candidate Adjuvanted With CpG 1018

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 43

03/24/2021

Daily Note

Pages: 3

First Participants Dosed in Phase 2/3 SPECTRA COVID-19 Vaccine Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 44

02/26/2021

Company Report

Pages: 6

Potential Universal Recommendation for Hepatitis B Vaccine and Multiple COVID-19 Vaccine Data Readouts in 2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 45

02/22/2021

Company Report

Pages: 7

European Commission Approves Heplisav-B for Hepatitis B Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 46

02/04/2021

Daily Note

Pages: 3

First Patient Dosed in Tetanus and Pertussis Vaccine Phase 1 Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 47

02/01/2021

Company Report

Pages: 6

A Plethora of Positive News for Dynavax''s COVID-19 Programs; Raising PT by $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 48

01/25/2021

Daily Note

Pages: 3

First Patient Dosed With Medigen''s COVID-19 Vaccine Adjuvanted with CpG 1018 in Phase 2 Trial in Taiwan

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 49

01/07/2021

Daily Note

Pages: 3

Strong Final Immunogenicity Data Posted for Patients Undergoing Hemodialysis Treated With Heplisav-B

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 50

12/23/2020

Daily Note

Pages: 3

First Participants Dosed in the Serum Institute of India''s Phase 1/2 Trial Evaluating its COVID-19 Vaccine With CpG 1018

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 51

12/11/2020

Company Report

Pages: 7

Positive CHMP Opinion for Heplisav-B in Hepatitis B

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 52

12/04/2020

Daily Note

Pages: 3

Strong Immune Responses From Clover''s COVID-19 Candidate With Dynavax''s CpG 1018 Adjuvant

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 53

11/16/2020

Daily Note

Pages: 3

Another COVID-19 Vaccine Candidate Utilizing CpG 1018 Enters Phase 1/2 Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 54

11/06/2020

Company Report

Pages: 6

3Q20 Results; Solid Heplisav-B Sales; CpG 1018 Supply Agreement Could Dramatically Increase Revenues; Raising PT by $2

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 55

10/13/2020

Daily Note

Pages: 3

First Patient Dosed in Phase 1 Trial Evaluating Medigen''s COVID-19 Vaccine Combined With Dynavax''s CpG 1018 Adjuvant

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 56

09/25/2020

Daily Note

Pages: 3

Clover''s COVID-19 Vaccine With CpG 1018 Continues to Move Forward in Development

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 57

09/15/2020

Company Report

Pages: 7

Dynavax and Valneva Announce Commercial Supply Agreement of CpG 1018 for Valneva''s COVID-19 Vaccine Candidate

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 58

09/10/2020

Daily Note

Pages: 3

Preliminary Phase 1/2 Results of Sinovac''s COVID-19 Vaccine Candidate Released

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 59

08/13/2020

Company Report

Pages: 7

Dynavax Announces Grant of $3.4 Million From the Bill - Melinda Gates Foundation

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 60

08/07/2020

Company Report

Pages: 6

Disappointing 2Q20 Heplisav-B Sales Due to COVID-19 Pandemic; Lowering PT by $2 to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party